Product Wiki · Recalls · EU Safety Gate (RAPEX)

Earrings — recall A12/00153/24

EU Safety Gate (RAPEX) · France · 2024-01-26 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/00153/24
Date of alert
2024-01-26
Country / jurisdiction
France
Risk level
Serious risk
Risk type
Chemical
Brand
1 2 3 Bijoux
Product category
Jewellery
Product type
Earrings
Barcode (EAN/GTIN)
3770000607222
Reported risk: Le produit libère une quantité excessive de nickel (valeur mesurée : 5,8 µg/cm²/semaine). Le nickel est un sensibilisant puissant et peut provoquer des réactions allergiques en cas de contact direct et prolongé avec la peau. Le produit n'est pas conforme au règlement REACH.
Action taken by the authority
Type of economic operator taking notified measure
Distributor
Category of measure
Withdrawal of the product from the market
Date of entry into force
01/01/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Risk Description (original English): The product releases an excessive amount of nickel (measured value: 5.8 µg/cm²/week). Nickel is a strong sensitiser and can cause allergic reactions if in direct and prolonged contact with the skin.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10011667

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.